var data={"title":"Letrozole: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Letrozole: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6442?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=letrozole-patient-drug-information\" class=\"drug drug_patient\">see &quot;Letrozole: Patient drug information&quot;</a> and <a href=\"topic.htm?path=letrozole-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Letrozole: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187285\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Femara</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187286\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>ACH-Letrozole;</li>\n      <li>Apo-Letrozole;</li>\n      <li>Auro-Letrozole;</li>\n      <li>Bio-Letrozole;</li>\n      <li>Femara;</li>\n      <li>JAMP-Letrozole;</li>\n      <li>Mar-Letrozole;</li>\n      <li>MED-Letrozole;</li>\n      <li>Nat-Letrozole;</li>\n      <li>PMS-Letrozole;</li>\n      <li>RAN-Letrozole;</li>\n      <li>Riva-Letrozole;</li>\n      <li>Sandoz-Letrozole;</li>\n      <li>Teva-Letrozole;</li>\n      <li>Van-Letrozole;</li>\n      <li>Zinda-Letrozole</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187319\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Aromatase Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187288\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Breast cancer, advanced (first- or second-line treatment):</b> Females: Postmenopausal: Oral: 2.5 mg once daily; continue until tumor progression</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Breast cancer, early (adjuvant treatment):</b> Females: Postmenopausal: Oral: 2.5 mg once daily for a planned duration of 5 years; discontinue at relapse.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Duration of therapy:</i> American Society of Clinical Oncology (ASCO) guidelines for Adjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer (Focused Update) recommend a maximum duration of 5 years of aromatase inhibitor therapy for postmenopausal women; aromatase inhibitors may be combined with tamoxifen for a total duration of up to 10 years of endocrine therapy. Refer to the guidelines for specific recommendations based on menopausal status and tolerability (Burstein 2014). Treatment with an additional 5 years of therapy (for a total of 10 years of aromatase inhibitor therapy) has demonstrated a significantly improved rate of disease-free survival and a decreased risk of disease recurrence and contralateral breast cancer (when compared to placebo), although overall survival was not significantly different between groups and bone-related adverse events occurred more frequently with letrozole versus placebo (Goss 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Breast cancer, early (extended adjuvant treatment):</b> Females: Postmenopausal: Oral: 2.5 mg once daily for a planned duration of 5 years (after 5 years of tamoxifen); discontinue at relapse. In clinical trials, letrozole was initiated within 3 months of discontinuing tamoxifen (Goss 2003; Jin 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Duration of therapy:</i> ASCO guidelines for Adjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer (Focused Update) recommend a maximum duration of 5 years of aromatase inhibitor therapy for postmenopausal women; aromatase inhibitors may be combined with tamoxifen for a total duration of up to 10 years of endocrine therapy. Refer to the guidelines for specific recommendations based on menopausal status and tolerability (Burstein 2014). Treatment with an additional 5 years of therapy (for a total of 10 years of aromatase inhibitor therapy) has demonstrated a significantly improved rate of disease-free survival and a decreased risk of disease recurrence and contralateral breast cancer (when compared to placebo), although overall survival was not significantly different between groups and bone-related adverse events occurred more frequently with letrozole versus placebo (Goss 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Off-label combinations:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Breast cancer, advanced, estrogen receptor-positive, HER2-negative:</b> Females: Oral: 2.5 mg once daily (in combination with palbociclib) until disease progression or unacceptable toxicity (Finn 2015) <b>or</b> 2.5 mg once daily (in combination with ribociclib) until disease progression or unacceptable toxicity (Hortobagyi 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Breast cancer, metastatic, hormone receptor-positive, HER2-positive:</b> Females: Oral: 2.5 mg once daily (in combination with lapatinib) until disease progression or unacceptable toxicity (Johnston 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Infertility/ovulation stimulation in anovulatory women with polycystic ovarian syndrome (PCOS; off-label use):</b> Oral: 2.5 to 7.5 mg daily on cycle days 3 to 7 (Franik 2014; Legro 2013; Legro 2014; Misso 2012). Up to 5 treatment cycles may be administered with the dose increased in subsequent cycles for nonresponse or poor ovulatory response as determined by progesterone levels; maximum dose 7.5 mg daily (Legro 2014). Additional trials may be necessary to further define the routine use of letrozole in infertile women with PCOS.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ovarian (epithelial) cancer, recurrent (off-label use):</b> Oral: 2.5 mg once daily; continue until disease progression or unacceptable toxicity (Ramirez 2008)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187289\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187290\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &ge;10 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;10 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187291\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment (Child-Pugh class C) and cirrhosis: 2.5 mg every other day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Noncirrhotic patients with elevated bilirubin: There are no dosage adjustments provided in the manufacturer's labeling (effect has not been determined).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187263\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Femara: 2.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2.5 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187248\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6743706\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer orally without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49104527\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187264\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Breast cancer in postmenopausal women:</b> Adjuvant treatment of hormone receptor-positive early breast cancer, extended adjuvant treatment of early breast cancer after 5 years of tamoxifen; treatment of advanced breast cancer with disease progression following antiestrogen therapy; first-line treatment of hormone receptor-positive or hormone receptor-unknown, locally-advanced, or metastatic breast cancer</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25473551\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Infertility/ovulation stimulation in anovulatory women with polycystic ovarian syndrome (PCOS); Ovarian (epithelial) cancer, recurrent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187326\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Femara may be confused with Famvir, femhrt, Provera</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Letrozole may be confused with anastrozole</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Letaris, a formerly marketed Dutch brand name product for letrozole, may be confused with Letairis, a US brand name for ambrisentan.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187255\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Edema (7% to 18%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (4% to 20%), dizziness (3% to 14%), fatigue (8% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Diaphoresis (&le;24%), night sweats (15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypercholesterolemia (3% to 52%), hot flash (6% to 50%), weight gain (2% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (9% to 17%), constipation (2% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (4% to 34%), arthralgia (8% to 25%), arthritis (7% to 25%), ostealgia (5% to 22%), back pain (5% to 18%), decreased bone mineral density (&le;5% to 15%), osteoporosis (&le;5% to 15%), bone fracture (10% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (6% to 18%), cough (6% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain (6% to 8%), hypertension (5% to 8%), chest wall pain (6%), peripheral edema (5%), cerebrovascular accident (2% to 3%; including hemorrhagic stroke, thrombotic stroke), thromboembolism (2% to 3%; including portal vein thrombosis, pulmonary embolism, thrombophlebitis, venous thrombosis), angina pectoris (1% to 2%), myocardial infarction (1% to 2%), transient ischemic attacks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Insomnia (6% to 7%), pain (5%), anxiety (&lt;5%), depression (&lt;5%), vertigo (&lt;5%), drowsiness (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (5%), alopecia (3% to 5%), pruritus (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight loss (6% to 7%), hypercalcemia (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (5% to 8%), vomiting (3% to 7%), abdominal pain (6%), anorexia (1% to 5%), dyspepsia (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Mastalgia (2% to 7%), urinary tract infection (6%), vaginal dryness (5%), vaginal hemorrhage (5%), vaginal irritation (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Metastases (2% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (7%), influenza (6%), viral infection (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Limb pain (4% to 10%), myalgia (7% to 9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Cataract (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal disease (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pleural effusion (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, angioedema, arterial thrombosis, blurred vision, cardiac failure, carpal tunnel syndrome, dysesthesia, dysgeusia, endometrial carcinoma, endometrial hyperplasia, erythema multiforme, eye irritation, fever, hepatitis, hypoesthesia, increased appetite, increased liver enzymes, increased thirst, irritability, leukopenia, memory impairment, nervousness, palpitations, paresthesia, stomatitis, tachycardia, tenosynovitis (trigger finger), thrombocytopenia, toxic epidermal necrolysis, urinary frequency, urticaria, vaginal discharge, xeroderma, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187268\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to letrozole or any component of the formulation; pregnancy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Hypersensitivity to other aromatase inhibitors; use in patients &lt;18 years of age; premenopausal endocrine status; breastfeeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187252\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause dizziness, fatigue, and somnolence; patients should be cautioned before performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Decreased bone mineral density: May cause decreases in bone mineral density (BMD). In one study, a decrease in hip BMD by 3.8% from baseline in letrozole-treated patients vs 2% in placebo at 2 years was demonstrated, however, while lumbar spine BMD was decreased, the difference was not statistically significant. Results of a safety study did demonstrate a decrease in lumbar spine BMD with letrozole (compared to tamoxifen). Osteoporosis and bone fractures have occurred at higher rates when compared to tamoxifen or to placebo. Monitor BMD.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Increased cholesterol: May increase total serum cholesterol. In patients treated with adjuvant therapy and cholesterol levels within normal limits, an increase of &ge;1.5 x ULN in total cholesterol (non-fasting) has been demonstrated in 8.2% of letrozole-treated patients (25% requiring lipid-lowering medications) vs 3.2% of tamoxifen-treated patients (16% requiring medications). Monitor cholesterol panel; may require antihyperlipidemics.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dose adjustment recommended in patients with cirrhosis or severe hepatic dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187313\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2A6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2A6 (strong)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187257\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10064&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Artesunate: CYP2A6 Inhibitors may decrease serum concentrations of the active metabolite(s) of Artesunate. CYP2A6 Inhibitors may increase the serum concentration of Artesunate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2A6 Substrates (High risk with Inhibitors): CYP2A6 Inhibitors (Strong) may decrease the metabolism of CYP2A6 Substrates (High risk with Inhibitors). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methadone: Aromatase Inhibitors may increase the serum concentration of Methadone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamoxifen: May decrease the serum concentration of Letrozole.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tegafur: CYP2A6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tegafur. Specifically, CYP2A6 inhibitors may inhibit the conversion of tegafur into its active metabolite, 5-fluorouracil. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187271\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Use is contraindicated in women with an established pregnancy.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Breast cancer: Letrozole is approved for the treatment of breast cancer in postmenopausal women. Based on the mechanism of action and data from animal reproduction studies, letrozole may cause fetal harm if used during pregnancy. A pregnancy test is recommended prior to therapy in women of reproductive potential and effective contraception should be used during therapy and for at least 3 weeks following the last dose.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Infertility associated with polycystic ovarian syndrome (PCOS): Letrozole is used off-label to induce ovulation in infertile anovulatory women with PCOS (Balen 2016; Franik 2014; Legro 2013; Legro 2014; Misso 2012). Baseline testing is done prior to letrozole therapy to rule out unexpected ovulation which prevents exposure in early pregnancy (Legro 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20547807\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if letrozole is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during therapy and for at least 3 weeks after the last dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187272\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Calcium and vitamin D supplementation are recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187261\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholesterol, hepatic function tests; bone density; pregnancy test (prior to treatment in females of reproductive potential).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">For infertility/ovarian stimulation (off-label use), a pregnancy test is recommended prior to initiation. Midluteal progestin concentrations (in a clinical study, nonresponse to treatment was defined as a progesterone concentration &lt;3 ng/mL during the midluteal phase; poor ovulatory response was defined as progesterone concentrations indicating ovulation but just above the cutoff point) (Legro 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187251\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Letrozole is a nonsteroidal competitive inhibitor of the aromatase enzyme system which binds to the heme group of aromatase, a cytochrome P450 enzyme which catalyzes conversion of androgens to estrogens (specifically, androstenedione to estrone and testosterone to estradiol). This leads to inhibition of the enzyme and a significant reduction in plasma estrogen (estrone, estradiol and estrone sulfate) levels. Letrozole does not appear to affect synthesis of adrenal or thyroid hormones, aldosterone, or androgens.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187267\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid and well absorbed; not affected by food</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: ~1.9 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding, plasma: Weak</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP3A4 and 2A6 to an inactive carbinol metabolite</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Terminal: ~2 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to steady state, plasma: 2 to 6 weeks; steady state serum concentrations are 1.5 to 2 times higher than single-dose values. In girls 3 to 9 years, steady state concentrations were 25% to 67% that of the mean adult values (Feuillan 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~90%; 6% as unchanged drug, 75% as glucuronide carbinol metabolite, 9% as unidentified metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187270\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Femara Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (30): $842.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Letrozole Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (30): $543.44</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187273\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Antif (PE);</li>\n      <li>Aromara (ID);</li>\n      <li>Avomit (HR);</li>\n      <li>Bretra (KR);</li>\n      <li>Eirfem (IE);</li>\n      <li>Elozora (RO);</li>\n      <li>Endofree (BD);</li>\n      <li>Esmara (KR);</li>\n      <li>Etruzyl (UA);</li>\n      <li>Famara (UA);</li>\n      <li>Femaplex (ID);</li>\n      <li>Femar (IS, NO);</li>\n      <li>Femara (AE, AR, AT, AU, BB, BD, BE, BG, BH, BO, BR, CH, CL, CN, CO, CY, CZ, DE, DK, EE, EG, ES, FI, FR, GB, GR, HK, HR, HU, IE, IL, IQ, IR, IT, JO, JP, KR, KW, LB, LT, LU, LV, LY, MT, MX, MY, NL, NO, NZ, OM, PE, PH, PK, PL, PR, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, SY, TH, TR, TW, UY, VE, VN, YE);</li>\n      <li>Femgard (CO);</li>\n      <li>Femolet (AU);</li>\n      <li>Fera (AU);</li>\n      <li>Fezol (BD);</li>\n      <li>Fu Rui (CN);</li>\n      <li>Gesamef (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Glotraz (LK);</li>\n      <li>Hentrozole (PH);</li>\n      <li>Lenara (KR);</li>\n      <li>Lenor (BD);</li>\n      <li>Lentronat (SG);</li>\n      <li>Lerozol (LK);</li>\n      <li>Letara (AU, NZ);</li>\n      <li>Letero (SG, TH);</li>\n      <li>Letoripe (PH);</li>\n      <li>Letov (LK, TH);</li>\n      <li>Letraz (ID);</li>\n      <li>Letrol (BD);</li>\n      <li>Letronat (MY);</li>\n      <li>Letrostad (PH);</li>\n      <li>Letroz (PH, PY);</li>\n      <li>Letvex (PH);</li>\n      <li>Letzo (IE);</li>\n      <li>Letzol (IN);</li>\n      <li>Lexel (BD);</li>\n      <li>Lezol (PH);</li>\n      <li>Lezra (ID, PH, SG, UA, VN);</li>\n      <li>Likarda (LV);</li>\n      <li>Losiral (EC);</li>\n      <li>Trodis (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Trozet (PH, TH, TW);</li>\n      <li>Zolet (LK);</li>\n      <li>Zolstro (CR, DO, GT, HN, NI, PA, SV)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Balen AH, Morley LC, Misso M, et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. <i>Hum Reprod Update.</i> 2016;22(6):687-708.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/27511809/pubmed\" target=\"_blank\" id=\"27511809\">27511809</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burstein HJ, Prestrud AA, Seidenfeld J, et al, &ldquo;American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women with Hormone Receptor-Positive Breast Cancer,&rdquo; <i>J Clin Oncol</i>, 2010, 28(23):3784-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/20625130/pubmed\" target=\"_blank\" id=\"20625130\">20625130</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burstein HJ, Temin S, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. <i>J Clin Oncol</i>. 2014;32(21):2255-2269.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/24868023/pubmed\" target=\"_blank\" id=\"24868023\">24868023</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Buzdar AU, Robertson JF, Eiermann W, et al, &ldquo;An Overview of the Pharmacology and Pharmacokinetics of the Newer Generation Aromatase Inhibitors Anastrozole, Letrozole, and Exemestane,&rdquo; <i>Cancer</i>, 2002, 95(9):2006-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/12404296/pubmed\" target=\"_blank\" id=\"12404296\">12404296</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coates AS, Keshaviah A, Thurlimann B, et al, &ldquo;Five Years of Letrozole Compared With Tamoxifen as Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98,&rdquo; <i>J Clin Oncol</i>, 2007, 25(5):486-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/17200148/pubmed\" target=\"_blank\" id=\"17200148\">17200148</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Femara (letrozole) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Femara (letrozole) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; April 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Feuillan P, Calis K, Hill S, Shawker T, Robey PG, Collins MT. Letrozole treatment of precocious puberty in girls with McCune-Albright syndrome: a pilot study. <i>J Clin Endocrinol Metab</i>. 2007;92:2100-2106.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/17405850/pubmed\" target=\"_blank\" id=\"17405850\">17405850</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. <i>Lancet Oncol</i>. 2015;16(1):25-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/25524798/pubmed\" target=\"_blank\" id=\"25524798\">25524798</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24563180\"></a>Franik S, Kremer JA, Nelen WL, Farquhar C. Aromatase inhibitors for subfertile women with polycystic ovary syndrome. <i>Cochrane Database Syst Rev</i>. 2014;2:CD010287.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/24563180/pubmed\" target=\"_blank\" id=\"24563180\">24563180</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goss PE, Ingle JN, Martino S, et al. A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer. <i>N Engl J Med</i>. 2003;349(19):1793-1802.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/14551341/pubmed\" target=\"_blank\" id=\"14551341\">14551341</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goss PE, Ingle JN, Pritchard KI, et al. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. <i>N Engl J Med</i>. 2016;375(3):209-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/27264120/pubmed\" target=\"_blank\" id=\"27264120\">27264120</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21550852\"></a>He D, Jiang F. Meta-analysis of letrozole versus clomiphene citrate in polycystic ovary syndrome. <i>Reprod Biomed Online</i>. 2011;23(1):91-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/21550852/pubmed\" target=\"_blank\" id=\"21550852\">21550852</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer.<i> N Engl J Med</i>. 2016;375(18):1738-1748.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/27717303/pubmed\" target=\"_blank\" id=\"27717303\">27717303</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jin H, Tu D, Zhao N, et al. Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. <i>J Clin Oncol</i>. 2012;30:718-721.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/22042967/pubmed\" target=\"_blank\" id=\"22042967\">22042967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. <i>J Clin Oncol</i>. 2009;27(33):5538-5546.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/19786658/pubmed\" target=\"_blank\" id=\"19786658\">19786658</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23531705\"></a>Kar S. Clomiphene citrate or letrozole as first-line ovulation induction drug in infertile PCOS women: a prospective randomized trial. <i>J Hum Reprod Sci</i>. 2012;5(3):262-265.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/23531705/pubmed\" target=\"_blank\" id=\"23531705\">23531705</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Legro RS. Ovulation induction in polycystic ovary syndrome: current options. <i>Best Pract Res Clin Obstet Gynaecol.</i> 2016;37:152-159. doi: 10.1016/j.bpobgyn.2016.08.001.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/27866938/pubmed\" target=\"_blank\" id=\"27866938\">27866938</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24151290\"></a>Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2013;98(12):4565-4592.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/24151290/pubmed\" target=\"_blank\" id=\"24151290\">24151290</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25006718\"></a>Legro RS, Brzyski RG, Diamond MP, et al; NICHD Reproductive Medicine Network. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. <i>N Engl J Med</i>. 2014;371(2):119-29. doi: 10.1056/NEJMoa1313517.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/25006718/pubmed\" target=\"_blank\" id=\"25006718\">25006718</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malloch L, Rhoton-Vlasak A. An assessment of current clinical attitudes toward letrozole use in reproductive endocrinology practices. <i>Fertil Steril</i>. 2013;100(6):1740-1744.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/24112529/pubmed\" target=\"_blank\" id=\"24112529\">24112529</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22431566\"></a>Misso ML, Wong JL, Teede HJ, et al. Aromatase inhibitors for PCOS: a systematic review and meta-analysis. <i>Hum Reprod Update.</i> 2012;18(3):301-312.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/22431566/pubmed\" target=\"_blank\" id=\"22431566\">22431566</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"NICE.2013\"></a>National Collaborating Centre for Women's and Children's Health. Fertility: assessment and treatment for people with fertility problems (Clinical guideline 156). London, UK : National Institute for Health and Clinical Excellence (NICE); February 2013. <a href=\"http://www.guideline.gov/content.aspx?id=43841\" target=\"_blank\">http://www.guideline.gov/content.aspx?id=43841</a>. Accessed March 6, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Institute for Occupational Safety and Health (NIOSH), &quot;NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.&quot; Available at <a href=\"http://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf</a>. Accessed January 21, 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18457865\"></a>Ramirez PT, Schmeler EM, Milam MR, et al, &ldquo;Efficacy of Letrozole in the Treatment of Recurrent Platinum- and Taxane-Resistant High-Grade Cancer of the Ovary or Peritoneum,&rdquo; <i>Gynecol Oncol</i>, 2008, 110(1):56-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/18457865/pubmed\" target=\"_blank\" id=\"18457865\">18457865</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simpson D, Curran MP, and Perry CM, &quot;Letrozole: A Review of Its Use in Postmenopausal Women With Breast Cancer,&quot; <i>Drugs</i>, 2004, 64(11):1213-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/15161328/pubmed\" target=\"_blank\" id=\"15161328\">15161328</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith IE and Dowsett M, &quot;Aromatase Inhibitors in Breast Cancer,&quot; <i>N Engl J Med</i>, 2003, 348(24):2431-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/12802030/pubmed\" target=\"_blank\" id=\"12802030\">12802030</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smyth JF, Gourley C, Walker G, et al. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. <i>Clin Cancer Res</i>. 2007;13(12):3617-3622.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/17575226/pubmed\" target=\"_blank\" id=\"17575226\">17575226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thurlimann B, Keshaviah A, Coates AS, et al, &quot;A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer,&quot; <i>N Engl J Med</i>, 2005, 353(26):2747-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/16382061/pubmed\" target=\"_blank\" id=\"16382061\">16382061</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tulandi T, Martin J, Al-Fadhli R, et al. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. <i>Fertil Steril</i>. 2006;85(6):1761-1765.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/16650422/pubmed\" target=\"_blank\" id=\"16650422\">16650422</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Winer EP, Hudis C, Burstein HJ, et al, &quot;American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Status Report 2004,&quot; <i>J Clin Oncol</i>, 2005, 23(3):619-29.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/15545664/pubmed\" target=\"_blank\" id=\"15545664\">15545664</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10064 Version 161.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F187285\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F187286\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F187319\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F187288\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F187289\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F187290\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F187291\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F187263\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F187248\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F6743706\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49104527\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F187264\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25473551\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F187326\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F187255\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F187268\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F187252\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F187313\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F187257\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F187271\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20547807\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F187272\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F187261\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F187251\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F187267\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F187270\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F187273\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10064|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=letrozole-patient-drug-information\" class=\"drug drug_patient\">Letrozole: Patient drug information</a></li><li><a href=\"topic.htm?path=letrozole-pediatric-drug-information\" class=\"drug drug_pediatric\">Letrozole: Pediatric drug information</a></li></ul></div></div>","javascript":null}